Accentia plans drug production plant; Sanofi/Merck JV gets animal health chief;

 @FierceBiotech: Is a bidding war for Genzyme looming? Report | Follow @FierceBiotech

> Accentia Biopharmaceuticals plans to revive discussions on a proposed production plant once it emerges from bankruptcy, according to a report in the St. Louis Business Journal. The plant would produce the experimental Revimmune for MS. Story

> Sanofi-Aventis and Merck have named Raul Kohan as the new CEO of their new joint venture on animal health. Kohan is currently president of Intervet/Schering-Plough. Report

> Ampio Pharmaceuticals has struck a deal to acquire DMI BioSciences, giving Ampio access to all rights, royalties and patents associated with DMI's drugs for male sexual dysfunction including premature ejaculation. Release

> Prolias Technologies, which supplies cancer researchers with research reagents, has spun out of Prolias, LLC. Release

And Finally... Childhood cancer survival is associated with increased risk of long-term abnormalities in cardiac function, according to a report in the July 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. Release

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.

VBL got the green light after the committee looked at unblinded overall survival data for the second pre-planned interim analysis.